Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.
Release Time:2025-04-30
Hits:
- Date:
- 2025-04-30
- Title of Paper:
- Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.
- Journal:
- Bioorganic & Medicinal Chemistry
- Summary:
- Recently approved multi-target inhibitors of receptor tyrosine kinases (RTKs) have significantly improved the clinical treatment of cancers. A series of N,N'-diarylureas incorporated with aromatic heterocycle have been designed, synthesized and evaluated as novel multi-target RTK inhibitors. The preliminary biological evaluation indicated that several compounds exhibited comparable potency with Sorafenib. Among them, compound 6f was identified as the most potent multikinase inhibitor of EGFR, KDR and FGFR1 with IC50 values of 14.83nM, 21.57nM, and 28.23nM, respectively. These compounds expanded the structural diversity of diarylureas as RTK inhibitors. The results demonstrated that compound 6f could be served as novel lead compound for further development of multi-target RTK inhibitors.
- Co-author:
- Yuanyuan Shan, Yalin Dong*
- Translation or Not:
- No
- Date of Publication:
- 2016-02-15
- Prev One:Design, Synthesis and Biological Evaluation of 2-Phenoxy-N-Phenylacetamides as Novel Anticancer Agents
- Next One:Treatment of a patient with severe hemorrhagic fever accompanied by infection with methicillinresistant Staphylococcus aureus, Acinetobacter baumannii, aspergillus and mucor: a case report.




